Sigma's Merger Still Looks Doubtful to Shaw -- Market Talk

Dow Jones06-17

0056 GMT - Competition concerns over Sigma Healthcare's proposed merger with Chemist Warehouse support the view of Shaw & Partners analyst Philip Pepe that the deal will need to change if it is to progress. Of the concerns listed in the competition regulator's statement of issues, Pepe is most wary of pharmacy retailing competition, privacy of rivals' data, and the potential for a reduction in choice of wholesale and franchise arrangements. He tells clients in a note that his unchanged forecasts assume that the merger won't go ahead. Shaw keeps a sell rating and A$1.00 target price on the stock, which is up 2.2% at A$1.185. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 16, 2024 20:56 ET (00:56 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444902712?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-17 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444902712","market":"other","top_or_hot":-1,"title":"Sigma's Merger Still Looks Doubtful to Shaw -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0056 GMT - Competition concerns over Sigma Healthcare's proposed merger with Chemist Warehouse support the view of Shaw &amp; Partners analyst Philip Pepe that the deal will need to change if it is to progress. Of the concerns listed in the competition regulator's statement of issues, Pepe is most wary of pharmacy retailing competition, privacy of rivals' data, and the potential for a reduction in choice of wholesale and franchise arrangements. He tells clients in a note that his unchanged forecasts assume that the merger won't go ahead. Shaw keeps a sell rating and A$1.00 target price on the stock, which is up 2.2% at A$1.185. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2024 20:56 ET (00:56 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sigma's Merger Still Looks Doubtful to Shaw -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSigma's Merger Still Looks Doubtful to Shaw -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0056 GMT - Competition concerns over Sigma Healthcare's proposed merger with Chemist Warehouse support the view of Shaw & Partners analyst Philip Pepe that the deal will need to change if it is to ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SJR","symbol_name":"肖氏通信","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2444902712","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444902712","pubTimestamp":1718585760,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0056 GMT - Competition concerns over Sigma Healthcare's proposed merger with Chemist Warehouse support the view of Shaw & Partners analyst Philip Pepe that the deal will need to change if it is to progress. Of the concerns listed in the competition regulator's statement of issues, Pepe is most wary of pharmacy retailing competition, privacy of rivals' data, and the potential for a reduction in choice of wholesale and franchise arrangements. He tells clients in a note that his unchanged forecasts assume that the merger won't go ahead. Shaw keeps a sell rating and A$1.00 target price on the stock, which is up 2.2% at A$1.185. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SJR":"肖氏通信","BK4100":"有线和卫星","SIG.AU":"SIGMA HEALTHCARE LTD","BK7103":"保健护理产品经销商"},"translate_title":"Shaw对Sigma的合并仍持怀疑态度——市场谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SJR":1,"SIG.AU":0.9},"content_text":"0056 GMT - Competition concerns over Sigma Healthcare's proposed merger with Chemist Warehouse support the view of Shaw & Partners analyst Philip Pepe that the deal will need to change if it is to progress. Of the concerns listed in the competition regulator's statement of issues, Pepe is most wary of pharmacy retailing competition, privacy of rivals' data, and the potential for a reduction in choice of wholesale and franchise arrangements. He tells clients in a note that his unchanged forecasts assume that the merger won't go ahead. Shaw keeps a sell rating and A$1.00 target price on the stock, which is up 2.2% at A$1.185. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2024 20:56 ET (00:56 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444902712"}